Aghajanian C et al. Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025. ESMO 2025;Abstract LBA44.
Akıllı H et al. First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. ESMO 2025;Abstract 1114P.
Barretina Ginesta MP et al. Final overall survival (OS) results from the randomized double-blind phase III AtTEND/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. ESMO 2025;Abstract LBA39.
Cibula D et al. Phase 3, randomized, double-blind, placebo (Pbo)-controlled ENGOT-ov43/GOG-3036/KEYLYNK-001 study of 1L chemotherapy (CT) ± pembrolizumab (Pembro) then maintenance (Maint) pembro ± olaparib (Ola) for advanced BRCA-nonmutated epithelial ovarian cancer (EOC): Analysis by HRD status. ESMO 2025; Abstract 1071P.
Clamp AR et al. ICON8B: GCIG phase III randomized trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk Stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis. ESMO 2025;Abstract 1064O.
Colombo N et al. Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study. ESMO 2025;Abstract LBA3.
Denys H et al. Quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms of disease or toxicity (Q-TWIST) results from the PRIMA/ENGOT-OV26/GOG-3012 final analysis. ESMO 2025;Abstract 1070P.
Eminowicz G et al. GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). ESMO 2025;Abstract 1221TiP.
Gaba Garcia L et al. Neoadjuvant dostarlimab in mismatch repair deficient (MMRd) stage II-III endometrioid endometrial cancer (EC): The GEICO137-E/NADIA study. ESMO 2025;Abstract 1224TiP.
González-Martín A et al. An open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO 01). ESMO 2025;Abstract 127TiP.
Kim SI et al. First-line niraparib maintenance therapy in BRCA wild-type, low-risk advanced ovarian cancer: The POLO trial. ESMO 2025;Abstract 1084P.
Lee J-Y et al. Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. ESMO 2025;Abstract 145P.
Li N et al. Fuzuloparib (FZPL) monotherapy or in combination with apatinib as first-line maintenance therapy in advanced ovarian cancer: Final analysis of the FZOCUS-1 trial. ESMO 2025;Abstract 1063O.
Makker V et al. Lenvatinib plus pembrolizumab (L + P) vs treatment of physician’s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309/KEYNOTE-775. ESMO 2025;Abstract 1119P.
Makker V et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 1 final analysis. ESMO 2025;Abstract 957P.
Moore KN et al. FIRST/ENGOT-OV44 trial: Does the addition of dostarlimab impact niraparib tolerability, exposure, or dose modification? ESMO 2025;Abstract 1101P.
Oaknin A et al. First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract 1065MO.
Olawaiye AB et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet 2025;405(10496):2205-16. Abstract
Powell MA et al. Post-hoc survival outcomes based on initial and subsequent treatment in patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. ESMO 2025;Abstract 1113P.
Ray-Coquard IL. Combining pembrolizumab plus weekly paclitaxel +/- bevacizumab for platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract Discussant.
Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.
Slomovitz BM et al. A randomized phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY Endometrial 01/GOG-3098/ENGOT-EN24. ESMO 2025;Abstract 1223TiP.
Westin S et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial. ESMO 2025;Abstract 1117P.
Wu X et al. Phase III study of camrelizumab plus famitinib versus platinum-based chemotherapy as first-line therapy for recurrent or metastatic cervical cancer. ESMO 2025;Abstract LBA38.